CLAIMS

1. A composition for use in the treatment of ocular surface diseases including corneal and conjunctival lesions, wherein the composition comprises a therapeutic amount of prostaglandin F2alpha or analogues, said composition being in a form suitable for topical application on the ocular surface and said composition being an emulsion.

2. The composition of claim 1, said composition being free of deleterious preservative.

3. The composition according to claim 1 or claim 2, wherein the composition is an aqueous solution, a viscous or semi-viscous gel, a suspension, a solid insert or an anionic or cationic emulsion.

4. The composition according to anyone of claims 1 to 3, wherein the composition is in the form of eye drops, artificial tears, gel or ointment.

5. The composition according to anyone of claims 1 ~~or claim~~to 4, which is sterile.

6. The composition according to anyone of claims 1 to 5, which is isoosmotic or hypoosmotic.

7. The composition according to anyone of claims 1 to 6, further comprising osmoprotectants, or other healing agents .

8. The composition according to anyone of claims 1 to 7, wherein the prostaglandin F2alpha analogue is selected from the group consisting of latanoprost, acid free

surface ocular conditions including corneal and conjunctival lesions in a patient in need thereof, wherein the patient is affected by glaucoma and the therapeutic amount of prostaglandin F2 alpha analogue is 0.004 to 0.005% in weight to the weight of the total composition.

15. The composition according to anyone of claims **1** to **12**, or according to claim **13** or **14**, for use in the treatment of surface ocular conditions including corneal and conjunctival lesions in a patient in need thereof, wherein the patient is not affected by glaucoma, and the therapeutic amount of prostaglandin F2 alpha analogue is 0.0001% to 0.004% in weight to the weight of the total composition, and the composition is administered during three to five days.

16. Use of a composition in the manufacture of a medicament for the treatment of ocular surface diseases including corneal and conjunctival lesions in a patient, wherein the medicament comprises a therapeutic amount of prostaglandin F2alpha or analogues, said medicament being in a form suitable for topical application on the ocular surface and said composition being an emulsion.

17. The use of claim **16**, wherein the medicament is free of deleterious preservative.

18. The use according to claim **16** or claim **17**, wherein the medicament is an aqueous solution, a viscous or semi-viscous gel, a suspension, a solid insert or an anionic or cationic emulsion.

19. The use according to anyone of claims **16** to **18**, wherein the medicament is in the form of eye drops, artificial tears, gel or ointment.